BACKGROUND: @entity1503 are a severe complication after allogeneic stem cell transplantation (allo- @entity12497 ) and their origin is often multifactorial or unknown. They are frequently refractory to standard therapy, which may include @entity230 and/or immunoglobulins. Mesenchymal stem cells (MSCs) are an attractive therapeutic tool in the allo- @entity12497 setting for the ability to enhance engraftment as well as acting as immunosuppressants for @entity2132 . There is no prior experience in the literature of the use of MSCs to treat @entity1503 after allo- @entity12497 . CASE REPORTS: In this work we report for the first time four cases of refractory posttransplant @entity1503 (three @entity1 with @entity882 and one with @entity1398 ) that were treated with MSCs from a third-party donor. MSCs were expanded from 100   mL of marrow obtained under standard good manufacturing practice conditions. Most @entity1 received more than one cell dose, and median dose of MSCs administered was 1       10(6) /kg. RESULTS: All @entity1 recovered normal blood counts, with a mean follow-up of 12.5 months. There were no adverse events related to MSC administration. CONCLUSION: MSC therapy may contribute to the recovery of refractory posttransplant @entity1897 in @entity1 undergoing allo- @entity12497 .

Allogeneic mesenchymal stem cell therapy for XXXX after hematopoietic stem cell transplantation.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity12497 :: ('MESH:C535780', 'Disease') :: ['SCT'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['Posttransplant cytopenias', 'cytopenias'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral cytopenias'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['graft-versus-host disease'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']
@entity1503 :: (MESH:D006402,Disease) :: ['refractory cytopenias']
